Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany; Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany; Klinik für Psychiatrie und Psychotherapie, Clienia Schlössli, Oetwil am See, Switzerland.
Eur Psychiatry. 2015 Feb;30(2):228-32. doi: 10.1016/j.eurpsy.2014.11.010. Epub 2014 Dec 30.
Affective disorders are associated with an increased risk of cardiovascular disease, which, at least partly, appears to be independent of psychopharmacological treatments used to manage these disorders. Reduced heart rate variability (SDNN) and a low Omega-3 Index have been shown to be associated with increased risk for death after myocardial infarction. Therefore, we set out to investigate heart rate variability and the Omega-3 Index in euthymic patients with bipolar disorders.
We assessed heart rate variability (SDNN) and the Omega-3 Index in 90 euthymic, mostly medicated patients with bipolar disorders (Bipolar-I, Bipolar-II) on stable psychotropic medication, free of significant medical comorbidity and in 62 healthy controls. Heart rate variability was measured from electrocardiography under a standardized 30 minutes resting state condition. Age, sex, BMI, smoking, alcohol consumption and caffeine consumption as potential confounders were also assessed.
Heart rate variability (SDNN) was significantly lower in patients with bipolar disorders compared to healthy controls (35.4 msec versus 60.7 msec; P<0.0001), whereas the Omega-3 Index did not differ significantly between the groups (5.2% versus 5.3%). In a linear regression model, only group membership (patients with bipolar disorders versus healthy controls) and age significantly predicted heart rate variability (SDNN).
Heart rate variability (SDNN) may provide a useful tool to study the impact of interventions aimed at reducing the increased risk of cardiovascular disease in euthymic patients with bipolar disorders. The difference in SDNN between cases and controls cannot be explained by a difference in the Omega-3 Index.
情感障碍与心血管疾病风险增加有关，而这种风险至少部分独立于用于治疗这些障碍的精神药理学治疗。已经表明，心率变异性（SDNN）降低和 Omega-3 指数低与心肌梗死后死亡风险增加有关。因此，我们着手研究双相情感障碍患者的心率变异性和 Omega-3 指数。
我们评估了 90 名处于稳定精神药物治疗且无重大合并症的双相情感障碍（双相 I 型、双相 II 型）患者的心率变异性（SDNN）和 Omega-3 指数。这些患者处于轻躁狂状态，以及 62 名健康对照者。心率变异性是在标准化的 30 分钟静息状态下通过心电图测量的。年龄、性别、BMI、吸烟、饮酒和咖啡因摄入等潜在混杂因素也进行了评估。
与健康对照组相比，双相情感障碍患者的心率变异性（SDNN）明显较低（35.4 毫秒对 60.7 毫秒；P<0.0001），而两组之间的 Omega-3 指数没有明显差异（5.2%对 5.3%）。在线性回归模型中，只有组别的归属（双相情感障碍患者与健康对照组）和年龄显著预测了心率变异性（SDNN）。
心率变异性（SDNN）可能是研究旨在降低双相情感障碍患者轻躁狂状态下心血管疾病风险增加的干预措施影响的有用工具。病例组和对照组之间 SDNN 的差异不能用 Omega-3 指数的差异来解释。
